Zepbound for obesity

How Zepbound (tirzepatide) is used in obesity, what the clinical evidence shows, and how it compares to other treatment options.

FDA-approved indicationZepbound is FDA-approved for obesity

Obesity: what it is

Obesity is a chronic disease defined by excess body fat that increases the risk of cardiovascular disease, type 2 diabetes, and other comorbidities. The American Medical Association recognized obesity as a disease in 2013. Standard threshold: BMI ≥30 (or ≥27 with a weight-related condition).

How Zepbound fits into obesity treatment

First-line: lifestyle modification (calorie deficit, structured physical activity, behavioral counseling). Pharmacotherapy is indicated for BMI ≥30 or ≥27 with comorbidity. GLP-1 receptor agonists (semaglutide/Wegovy, liraglutide/Saxenda) and the dual GLP-1/GIP agonist tirzepatide (Zepbound) are now first-line drug therapy due to 14-22% mean body-weight reduction in trials. Older agents (phentermine, naltrexone-bupropion, orlistat) remain options. Bariatric surgery for BMI ≥40 or ≥35 with severe comorbidity.

Zepbound works by: Tirzepatide is a dual incretin agonist: it hits both the GLP-1 receptor (like semaglutide) and the GIP receptor (which semaglutide doesn't). The combination produces stronger appetite suppression and better glycemic effect than GLP-1 alone, which translates to more weight loss in head-to-head trials (SURMOUNT studies showed ~20% body weight loss at the 15mg dose).

Who qualifies for Zepbound for obesity

Same indications as Wegovy: BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Contraindicated in personal/family history of medullary thyroid cancer or MEN2.

Clinical evidence

20.9% mean body-weight reduction at 72 weeks (15 mg dose)

Trial: SURMOUNT-1 (NCT04184622) · vs 3.1% with placebo · N = 2,539

How Zepbound compares to other obesity treatments

Frequently asked about obesity

Is obesity considered a disease?: Yes. The American Medical Association formally recognized obesity as a disease in 2013, and the World Health Organization classifies it as a chronic condition. This framing matters clinically (it justifies long-term treatment) and financially (it supports insurance coverage of pharmacotherapy).
How much weight loss is clinically meaningful?: 5-10% body-weight reduction sustained for 6+ months produces measurable improvement in blood pressure, lipids, glucose control, and quality of life. GLP-1 trials produce 14-22% mean weight loss — well above the threshold for clinical benefit.
Do I need to fail diet and exercise before getting a GLP-1?: Clinical guidelines no longer require documented failure of lifestyle intervention before initiating pharmacotherapy if BMI criteria are met. Many insurance plans, however, do require documented prior attempts. A program with an insurance concierge handles this paperwork for you.
Will I have to take a GLP-1 forever?: Trial extension data shows roughly two-thirds of lost weight returns within 12-18 months of discontinuation. The clinical model is chronic-disease treatment, similar to managing hypertension or hyperlipidemia. Some patients move to a lower maintenance dose rather than a full stop.